Teva to present SOLARIS Phase 3 post hoc olanzapine LAI data
Teva says it will present new post hoc data for olanzapine LAI (TEV-'749) from its SOLARIS Phase 3 trial, focused on stabilization and long-term efficacy for schizophrenia treatment in adults.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.